L.P. Ra Capital Management Buys Shares of Vor Biopharma Inc. $VOR
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
L.P. Ra Capital Management, insider at Vor Biopharma Inc. ($VOR), bought 57,162 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Vor Biopharma Inc. Stock Down 36.6%
Shares of Vor Biopharma Inc. ($VOR) traded around $14.36 on Saturday, down 36.6% for the day.
Vor Biopharma Inc. Earnings
Analysts Set New Price Targets
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Get Vor Biopharma Inc. alerts
New 13F filings, insider trades, and analyst moves on $VOR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.